查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011038

有機藥用輔料市場：依產品種類、應用、劑型及原料分類－2026-2032年全球市場預測

Organic Pharmaceutical Excipients Market by Product Type, Application, Form, Source - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，有機藥用輔料市場價值將達到 138 億美元，到 2026 年將成長至 150.9 億美元，到 2032 年將達到 270.5 億美元，複合年成長率為 10.08%。

主要市場統計數據
基準年 2025 138億美元
預計年份：2026年 150.9億美元
預測年份 2032 270.5億美元
複合年成長率 (%) 10.08%

這本權威的入門書籍說明了為什麼有機藥用輔料現在對配方成功、供應鏈連續性、法規遵從性和永續性結果產生重大影響。

有機藥用輔料在藥物研發和商業化生產中發揮核心作用，但其重要性往往被低估。這些功能多樣的物質——粘合劑、填充劑、崩壞、潤滑劑和穩定劑——影響藥物的穩定性、生物利用度、可生產性和患者接受度等關鍵特性。隨著監管要求的提高和製劑的日益複雜，輔料的選擇、採購和表徵已從簡單的常規環節演變為對研發管線成功至關重要的策略決定因素。

科學、監管、永續性和數位化趨勢如何交織，並重塑整個產業的輔料選擇、供應模式和策略配方開發重點？

有機藥用輔料領域正經歷一場變革，這主要歸因於多種因素的共同作用。聚合物化學和製程工程領域的科學進步，使得新型輔料能夠提供更佳的緩釋性能、穩定性以及更佳的患者體驗。同時，監管環境也在不斷變化，對可追溯性、雜質控制和功能論證提出了更高的要求，迫使生產商投入更多資源進行更深入的分析和文件編制。

該評估旨在評估美國累積關稅措施如何重塑整個醫藥輔料供應鏈的籌資策略、供應商選擇和供應鏈韌性。

美國實施的累積關稅政策，為全球製造商和合約服務供應商的輔料採購和供應鏈規劃帶來了新的複雜性。關稅的疊加增加了接收成本，促使企業將生產轉移到近岸地區並尋求供應商多元化，同時迫使買家重新評估長期合約和安全庫存策略。為此，許多相關人員正在重新認證供應商，並梳理關鍵組件，以識別可能因關稅而加劇的單一故障點。

透過按產品類型、應用、劑型和來源對輔料進行分類，我們可以確定關鍵創新領域、配方限制以及開發人員的供應商選擇優先事項。

深入了解產品細分有助於明確輔料領域創新與風險的交會點。根據產品類型，市場包括纖維素衍生物、明膠、無機鹽、澱粉和糊精、醣類以及聚合物。纖維素衍生物包括羥丙基甲基纖維素和微晶纖維素；無機鹽包括磷酸鈣和硬脂酸鎂；澱粉和糊精包括玉米粉和馬鈴薯澱粉；醣類和聚合物包括乳糖、甘露醇和蔗糖。這種層級分類系統揭示了哪些子細分市場與緩釋製劑、片劑可壓性或注射劑製劑最為相關，從而為每個類別提供有針對性的分析和供應保障策略。

美洲、歐洲、中東和非洲以及亞太地區的區域供應趨勢和法規結構如何決定籌資策略、製造地選擇和合規優先事項。

區域趨勢對輔料原料的供應、法規要求和客戶偏好有顯著影響。在美洲，關鍵的無菌製劑和口服製劑的本地化生產受到支持，重點在於供應鏈整合、提高生產能力和嚴格的監管文件編制。歐洲、中東和非洲地區的情況各不相同，歐洲部分地區的監管協調性較強，而其他地區則面臨日益嚴重的永續性問題和物流複雜性，這些問題影響著分銷和倉儲策略。亞太地區是化學中間體的主要製造地，也是合約研發生產機構（CDMO）快速成長的市場，該地區的供應商正不斷增加對品質系統的投資，以滿足全球標準。

競爭格局的關鍵變化表明，品質差異化、整合開發服務和永續發展措施正在重新定義供應商價值提案和客戶選擇標準。

輔料供應商之間的競爭格局正沿著三大維度演變：品質差異化、附加價值服務整合以及永續發展領域的領先地位。主要企業正加大對分析能力、即時放行偵測和製劑開發支援的投資，以加快客戶開發週期並降低技術應用門檻。同時，各企業也在拓展服務範圍，包括共同開發、法規文件支援和客製化包裝，以期與製藥和生物技術公司建立策略夥伴關係。

為配方、採購和品質管理人員提供切實可行的優先建議，以增強韌性、加快發展並滿足永續性期望。

產業領導企業應採取一系列切實可行的因應措施，以掌握機會並管控瞬息萬變的輔料市場中的風險。首先，他們需要主動防範後期替代風險，將輔料選擇納入早期配方決策階段，並組成由採購、法規和分析化學部門組成的跨職能團隊。其次，他們需要透過認證地理位置分散的替代供應商、進行近岸生產或評估契約製造夥伴關係等方式，以實現籌資策略多元化，進而降低關稅和物流風險。

採用嚴謹的混合方法研究途徑，結合技術文獻、監管分析和從業者訪談，在透明的條件下檢驗了趨勢和供應商能力。

支持這些研究結果的調查方法結合了對同行評審文獻、監管指導文件、技術專著和公開文件的系統性回顧，以及對製劑科學家、採購主管和品質經理的定向訪談。分析方面，重點是透過技術文件和案例研究相互檢驗供應商的能力和流程創新，同時透過審查主要衛生監管機構的最新指導和動態來評估監管影響。

簡要概述了輔料為何已成為產品品質、法規應對力和永續生產成果的策略促進因素。

總之，有機藥用輔料不再是生產過程中的被動成分，而是影響產品性能、監管風險和供應鏈韌性的策略促進因素。科學進步、不斷變化的監管預期、關稅壓力和永續性需求，都在促使輔料選擇和供應商合格的標準不斷提高。那些在研發早期階段就積極運用輔料策略、實現採購多元化並要求供應商提供更高分析透明度的企業，將能夠降低下游風險並最大限度地提高配方效益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：有機藥用輔料市場：依產品類型分類

  • 纖維素衍生物
    • 羥丙基甲基纖維素
    • 微晶纖維素
  • 明膠
  • 無機鹽
    • 磷酸鈣
    • 硬脂酸鎂
  • 澱粉和糊精
    • 玉米澱粉
    • 馬鈴薯澱粉
  • 醣類和聚合物
    • 乳糖
    • 甘露醇
    • 蔗糖

第9章：有機藥用輔料市場：依應用領域分類

  • 注射藥物
  • 眼藥水
  • 口服固體製劑
    • 膠囊
    • 藥片
  • 外用

第10章：有機藥用輔料市場：以劑型分類

  • 凝膠
  • 顆粒
  • 液體
  • 粉末

第11章：有機藥用輔料市場：依來源分類

  • 自然的
  • 半合成
  • 合成

第12章：有機藥用輔料市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：有機藥用輔料市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：有機藥用輔料市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國有機藥用輔料市場

第16章：中國有機藥用輔料市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Archer Daniels Midland Company
  • Ashland Global Holdings Inc.
  • Associated British Foods plc
  • BASF SE
  • Cargill Incorporated
  • Croda International Plc
  • DFE Pharma International Ltd.
  • DuPont de Nemours Inc.
  • Evonik Industries AG
  • Gattefosse SAS
  • Ingredion Incorporated
  • Innophos Holdings, Inc.
  • International Flavors & Fragrances Inc.
  • JRS Pharma GmbH & Co. KG
  • Kerry Group Plc
  • Merck KGaA
  • Roquette Freres SA
  • Shin-Etsu Chemical Co., Ltd.
  • The Lubrizol Corporation
  • Wacker Chemie AG
Product Code: MRR-433BAD49EDB9

The Organic Pharmaceutical Excipients Market was valued at USD 13.80 billion in 2025 and is projected to grow to USD 15.09 billion in 2026, with a CAGR of 10.08%, reaching USD 27.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.80 billion
Estimated Year [2026] USD 15.09 billion
Forecast Year [2032] USD 27.05 billion
CAGR (%) 10.08%

An authoritative introduction framing why organic pharmaceutical excipients now determine formulation success, supply continuity, regulatory compliance, and sustainability outcomes

Organic pharmaceutical excipients occupy a central but often underappreciated position in drug development and commercial manufacture. These functional materials - spanning binders, fillers, disintegrants, lubricants, and stabilizers - influence critical attributes such as stability, bioavailability, manufacturability, and patient acceptability. As regulatory expectations intensify and formulation complexity increases, the selection, sourcing, and characterization of excipients have evolved from routine inputs to strategic determinants of pipeline success.

Consequently, development teams and procurement leaders are aligning earlier in the product lifecycle to integrate excipient considerations with analytical, regulatory, and sustainability objectives. This integration reduces downstream risk, shortens timelines, and supports lifecycle management decisions. In short, understanding excipient performance and supply dynamics is essential for robust pharmaceutical innovation and for preserving margins in increasingly cost- and quality-sensitive manufacturing environments.

How converging scientific, regulatory, sustainability, and digital trends are reshaping excipient selection, supply models, and strategic formulation priorities across the industry

The landscape for organic pharmaceutical excipients is undergoing transformative shifts driven by multiple convergent forces. Scientific advances in polymer chemistry and process engineering are enabling excipients that deliver controlled release, improved stability, and enhanced patient experience. At the same time, regulatory frameworks are evolving to demand greater traceability, impurity control, and functional justification, prompting manufacturers to invest in analytical depth and documentation.

Moreover, sustainability criteria and circularity commitments are reshaping raw material sourcing, with formulators prioritizing renewable feedstocks and low-impact production methods. Digitalization is improving quality assurance through data-rich manufacturing execution systems and predictive analytics, while strategic consolidation among suppliers is changing procurement dynamics. Taken together, these shifts are elevating excipients from commodity status to strategic assets integral to portfolio differentiation and manufacturing resilience.

Evaluating how the cumulative United States tariff measures are reshaping sourcing strategies, supplier qualification, and supply chain resilience across pharmaceutical excipient supply networks

The implementation of cumulative tariffs in the United States has introduced new layers of complexity into excipient sourcing and supply chain planning for global manufacturers and contract service providers. Tariff overlays increase landed costs, incentivize nearshoring or supplier diversification, and force buyers to reassess long-term contracts and safety-stock strategies. In response, many stakeholders are conducting supplier requalification workstreams and mapping critical components to identify single-point vulnerabilities that tariffs could exacerbate.

Transition strategies include qualifying alternate suppliers outside tariff-impacted jurisdictions, investing in regional manufacturing capacity, and adjusting procurement cadence to smooth cost volatility. In addition, formulators and supply chain leaders are accelerating conversations with regulators about material substitutions and process changes to ensure continuity without compromising compliance. Thus, tariffs are not only a cost issue but a catalyst for supply chain modernization and strategic sourcing that can improve resilience over the long term.

Segmenting excipients by product type, application, form, and source to reveal innovation hot spots, formulation constraints, and supplier qualification priorities for developers

A meaningful understanding of product segmentation clarifies where innovation and risk intersect within the excipient landscape. Based on product type, the market includes cellulose derivatives, gelatin, inorganic salts, starches and dextrins, and sugars and polymers, with cellulose derivatives further differentiated into hydroxypropyl methylcellulose and microcrystalline cellulose, inorganic salts including calcium phosphate and magnesium stearate, starches and dextrins such as corn starch and potato starch, and sugars and polymers encompassing lactose, mannitol, and sucrose. This layered taxonomy reveals which subsegments are most relevant for controlled-release systems, tablet compression properties, or parenteral formulations and suggests targeted analytical and supply assurances for each category.

From an application perspective, excipients support injectable, ophthalmic, oral solid dosage, and topical forms, while oral solid dosage is further split into capsule and tablet considerations, underscoring differences in disintegration profiles and lubricant needs. Form factors span gel, granule, liquid, and powder, each presenting distinct process integration and stability requirements. Finally, source classification into natural, semi-synthetic, and synthetic raw materials affects sustainability narratives, impurity risk profiles, and regulatory substantiation pathways. When these segmentation lenses are combined, they provide a practical framework for prioritizing R&D efforts, supplier audits, and quality control investments.

How regional supply dynamics and regulatory frameworks across the Americas, Europe Middle East & Africa, and Asia-Pacific determine sourcing strategies, manufacturing placement, and compliance priorities

Regional dynamics materially shape raw material availability, regulatory expectations, and customer preference in excipients. The Americas region often emphasizes supply chain integration, manufacturing capacity expansion, and stringent regulatory documentation, supporting localized production for critical sterile and oral dosage inputs. Europe, Middle East & Africa presents a heterogeneous landscape with strong regulatory harmonization in parts of Europe, a growing interest in sustainability credentials, and logistical complexities in other territories that influence distribution and warehousing strategies. Asia-Pacific serves as both a major manufacturing hub for chemical intermediates and a fast-growing market for contract development and manufacturing, with regional suppliers increasingly investing in quality systems to meet global standards.

These regional distinctions affect strategic choices such as geographic diversification of suppliers, placement of safety stock, and where to locate capacity for product families that require specific excipient grades. Consequently, biopharma and generics companies are aligning manufacturing footprints and procurement policies with regional strengths to balance cost, compliance, and responsiveness to demand shifts.

Key competitive shifts showing how quality differentiation, integrated development services, and sustainability commitments are redefining supplier value propositions and customer selection

Competitive dynamics among excipient suppliers are evolving along three primary vectors: quality differentiation, integration of value-added services, and sustainability leadership. Leading manufacturers are investing in enhanced analytical capabilities, real-time release testing, and formulation support to accelerate customer development cycles and reduce technical barriers to adoption. Parallel to this, companies are expanding service offerings that include co-development, regulatory dossier support, and customized packaging to win strategic partnerships with pharma and biotech firms.

In addition, a growing cohort of suppliers is prioritizing lower environmental footprint processes and traceable raw materials to meet customer sustainability commitments and to preempt tightening regulatory scrutiny. Mergers, strategic partnerships, and targeted greenfield investments are further concentrating certain capabilities, while smaller, specialized producers continue to differentiate through niche functional chemistries or regional supply advantages. Together, these moves are redefining how value is delivered in excipient supply chains and how customers evaluate long-term supplier risk and opportunity.

Practical and prioritized recommendations for formulation, procurement, and quality leaders to bolster resilience, accelerate development, and meet sustainability expectations

Industry leaders should adopt an actionable portfolio of responses to capture opportunity and manage risk in the evolving excipient environment. First, integrate excipient selection into early formulation decisions by embedding cross-functional teams that include procurement, regulatory, and analytical chemistry to preempt late-stage substitution risks. Second, diversify sourcing strategies by qualifying alternate suppliers across geographies and by evaluating nearshore manufacturing or contract manufacturing partnerships to mitigate tariff and logistic exposure.

Third, accelerate investments in supplier audits and advanced analytics for impurity profiling, endotoxin control, and supply chain visibility to support regulatory submissions and quality consistency. Fourth, prioritize sustainability through supplier engagement on raw material provenance, energy efficiency, and waste reduction to align with customer expectations and corporate ESG goals. Finally, pursue strategic collaborations with suppliers that offer co-development services and technical support to shorten timelines and reduce development risk. Implementing these measures will strengthen resilience and support differentiated product outcomes.

A rigorous mixed-methods research approach combining technical literature, regulatory analysis, and practitioner interviews to validate trends and supplier capabilities with transparent assumptions

The research methodology underpinning these insights combined a structured review of peer-reviewed literature, regulatory guidance documents, technical monographs, and public filings with targeted interviews of formulation scientists, procurement executives, and quality leaders. Analytical emphasis was placed on cross-validating supplier capabilities and process innovations through technical dossiers and case histories, while regulatory impacts were assessed by reviewing recent guidance and enforcement trends from major health authorities.

Where direct market metrics were relevant, data were corroborated across multiple independent sources and validated through practitioner interviews. The approach prioritized transparency in assumptions and traceability of primary inputs, ensuring that observed trends reflect corroborated industry behavior rather than isolated anecdotes. This mixed-methods approach balances depth of technical insight with practical relevance for decision makers.

A concise synthesis underscoring why excipients have become strategic enablers for product quality, regulatory resilience, and sustainable manufacturing outcomes

In conclusion, organic pharmaceutical excipients are no longer passive components in manufacturing; they are strategic enablers that influence product performance, regulatory risk, and supply chain resilience. Scientific advances, evolving regulatory expectations, tariff pressures, and sustainability imperatives are collectively raising the bar for excipient selection and supplier qualification. Organizations that proactively integrate excipient strategy into early development, diversify sourcing, and demand higher analytical transparency from suppliers will reduce downstream risk and unlock formulation advantages.

Looking ahead, the intersection of digital quality systems, greener raw material sourcing, and supplier co-development will define competitive differentiation. Stakeholders who translate these imperatives into actionable procurement, R&D, and quality practices will be best positioned to deliver reliable, compliant, and patient-centric pharmaceutical products.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organic Pharmaceutical Excipients Market, by Product Type

  • 8.1. Cellulose Derivatives
    • 8.1.1. Hydroxypropyl Methylcellulose
    • 8.1.2. Microcrystalline Cellulose
  • 8.2. Gelatin
  • 8.3. Inorganic Salts
    • 8.3.1. Calcium Phosphate
    • 8.3.2. Magnesium Stearate
  • 8.4. Starches And Dextrins
    • 8.4.1. Corn Starch
    • 8.4.2. Potato Starch
  • 8.5. Sugars And Polymers
    • 8.5.1. Lactose
    • 8.5.2. Mannitol
    • 8.5.3. Sucrose

9. Organic Pharmaceutical Excipients Market, by Application

  • 9.1. Injectable
  • 9.2. Ophthalmic
  • 9.3. Oral Solid Dosage
    • 9.3.1. Capsules
    • 9.3.2. Tablets
  • 9.4. Topical

10. Organic Pharmaceutical Excipients Market, by Form

  • 10.1. Gel
  • 10.2. Granule
  • 10.3. Liquid
  • 10.4. Powder

11. Organic Pharmaceutical Excipients Market, by Source

  • 11.1. Natural
  • 11.2. Semi Synthetic
  • 11.3. Synthetic

12. Organic Pharmaceutical Excipients Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Organic Pharmaceutical Excipients Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Organic Pharmaceutical Excipients Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Organic Pharmaceutical Excipients Market

16. China Organic Pharmaceutical Excipients Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Archer Daniels Midland Company
  • 17.6. Ashland Global Holdings Inc.
  • 17.7. Associated British Foods plc
  • 17.8. BASF SE
  • 17.9. Cargill Incorporated
  • 17.10. Croda International Plc
  • 17.11. DFE Pharma International Ltd.
  • 17.12. DuPont de Nemours Inc.
  • 17.13. Evonik Industries AG
  • 17.14. Gattefosse SAS
  • 17.15. Ingredion Incorporated
  • 17.16. Innophos Holdings, Inc.
  • 17.17. International Flavors & Fragrances Inc.
  • 17.18. JRS Pharma GmbH & Co. KG
  • 17.19. Kerry Group Plc
  • 17.20. Merck KGaA
  • 17.21. Roquette Freres S.A.
  • 17.22. Shin-Etsu Chemical Co., Ltd.
  • 17.23. The Lubrizol Corporation
  • 17.24. Wacker Chemie AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CALCIUM PHOSPHATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CALCIUM PHOSPHATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CALCIUM PHOSPHATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MAGNESIUM STEARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MAGNESIUM STEARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MAGNESIUM STEARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CORN STARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CORN STARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CORN STARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POTATO STARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POTATO STARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POTATO STARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LACTOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LACTOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LACTOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MANNITOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MANNITOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MANNITOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUCROSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUCROSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUCROSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GRANULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GRANULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GRANULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SEMI SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SEMI SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SEMI SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INORGANIC SALTS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCHES AND DEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ORGANIC PHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)